Huiyu Pharmaceuticals (688553.SH): Docetaxel injection approved by the US FDA

Huiyu Pharmaceutical (688553.SH) announced that the company recently received notification that its product Docetaxel for Injection has been approved for Abbreviated New Drug Application (ANDA). Docetaxel for Injection is used for the treatment of advanced or metastatic breast cancer, non-small cell lung cancer, head and neck cancer, pancreatic cancer, stomach cancer, melanoma, and soft tissue sarcoma, showing certain effectiveness. The approval of Docetaxel for Injection by the US FDA, signifies that the company has obtained the qualification to sell products in the US market. This will help the company expand sales in the US market, strengthen the product supply chain, enrich the product portfolio, and further solidify the foundation for sustainable development in international markets.